ClinicalTrials.gg
CompletedNCT01922102BrillianceUpdated Jun 24, 2019Results posted

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

A Phase 3 interventional study of Ranibizumab 0.5mg and Ranibizumab 0.5 mg in Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM), sponsored by Novartis Pharmaceuticals. Completed at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
6th of 45
457 · median 62
Started
2013
with 5 others
Phase 3
11 of 45
none open now
Registered
36th of 45
by date
Lead sponsor
9 of 45
Novartis Pharmaceuticals

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 6th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 36th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

Read the detailed description

This was a phase III, multi-center, randomized, double-masked, active-controlled study comparing 0.5 mg ranibizumab vs. vPDT therapy. The study included 15 scheduled visits over 12 months, and there were to be two additional visits (2a, 3a) for subset of patients in whom PK analysis were performed.

There were 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients entered the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria were met and were randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or Group III vPDT (randomization ratio of 2:2:1) and received first treatment of either a ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the clinical center within 7 days to undergo safety assessments as well as assessments of the effect of treatment by the evaluating investigator. The following visits were performed at one month intervals starting at Visit 4 and continuing through Visit 14. At all monthly visits (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for group III) the decision for treatment were made by the evaluating investigator based on the VA stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at all following monthly visits for all three groups one of the three options can recommended by evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT. The treating investigator were then perform treatment based on randomization and masking requirements.

At each monthly visit, patients had a safety evaluation by the evaluating investigator prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations and evaluation of adverse events and vital signs. Routine hematology, chemistry, and urinalysis profiles were obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12 several procedures and assessments were performed which are required at study completion visit.

03

Conditions studied

  • Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Keywords

  • vision loss,PM,CNV,ranibizumab,verteporfinPDT,Brilliance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual impairment due to CNV secondary to PM.
  • Best corrected visual acuity in the study eye > 24 and \< 78 ETDRS letters.
  • High myopia (> -6D),
  • anterio-posterior elongation > 26 mm; posterior changes compatible with the pathologic myopia.
  • Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.

Exclusion criteria

Exclusion Criteria:

  • Some preexisting eye disorders or systemic diseases;-Blood pressure > 150/90 mmHg
  • Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF or verteporfin PDT in the study eye
  • Intravitreal treatment with or intraocular surgery within last 3 months in the study eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    Group I

    0.5 mg ranibizumab driven by visual acuity stability criteria

    Drug: Ranibizumab 0.5mg

  • Experimental
    Group II

    0.5 mg ranibizumab driven by disease activity criteria

    Drug: Ranibizumab 0.5 mg

  • Active comparator
    Group III

    verteporfin PDT

    Drug: Verteporfin PDT

Interventions

  • 0.5 mg ranibizumab (intravitreal injections)

    Also known as: Lucentis

  • 0.5 mg ranibizumab (intravitreal injections)

    Also known as: Lucentis

  • Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application

    Also known as: Visudyne

06

What researchers measure

Primary outcomes

  1. Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3

    Best corrected visual acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.

    Time frame: From Baseline to Month 3

Secondary outcomes

  1. Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6

    Best corrected visual acuity (BCVA) was tested using the early treatment diabetic retinopathy study (ETDRS) VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 6.

    Time frame: From Baseline to Month 6

  2. The Average Change in BCVA Score From Baseline to Month 1 Through Month 12

    Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 12

    Time frame: From Baseline to Month 12

  3. Mean Change From Baseline in Visual Acuity Over Time

    Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.

    Time frame: Change from baseline at months 3, 6, and 12

  4. Categorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye

    ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.

    Time frame: From Baseline to Month 12

  5. Mean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)

    Central sub-field thickness (CSFT) is a variable assessed via Optical Coherence Tomography (OCT). OCT was performed prior to any study drug administration to assess presence of intra, subretinal fluid, or increase of CSFT.

    Time frame: Baseline, Month 3, Month 6, and Month 12

  6. Number of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12

    CNV leakage is assessed via fluorescein angiography (center involvement) category: definite, questionable, absent, can't grade, and missing.

    Time frame: From Baseline until Month 12

  7. NEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12

    The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.

    Time frame: Change from baseline at month 3, 6 and 12

  8. Number of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups

    To assess treatment pattern with ranibizumab

    Time frame: From Baseline to Month 12

07

Results

Posted Jun 24, 2019

Participant flow

Randomized Set: consisted of all randomized patients. Patients were considered randomized when they had been given a randomization number.

Participant flow — Overall Study
MilestoneGroup IGroup IIGroup III
Started18218491
Completed17317583
Not completed998
Withdrew: Withdrawal by subject737
Withdrew: Physician decision021
Withdrew: Adverse event120
Withdrew: Lost to follow-up100
Withdrew: Administrative problems020

Outcome measures

PrimaryChange From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3

Best corrected visual acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.

Time frame:
From Baseline to Month 3
Reported as:
Mean · ETDRS letters
Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3
ETDRS lettersGroup IGroup IIGroup III
Baseline53.7 ± 12.6554.2 ± 13.0152.6 ± 12.29
Average Month 1 to Month 363.1 ± 12.8063.9 ± 13.2857.1 ± 13.21
Statistical analysis
  • Group I vs Group III · Cochran-Mantel-Haenszel · p = <0.001 (Superiority could be claimed if the corresponding one-sided p-value was ≤ 0.025/2 = 0.0125, or if both one-sided p-values were ≤ 0.025.) · Mean difference (net): 5.2 · 95% CI 3.3 to 7.1Differences in LS means and the two-sided 95% CIs are estimated from pairwise ANOVA (stratified) model.
  • Group II vs Group III · Cochran-Mantel-Haenszel · p = <0.001 (Superiority could be claimed if the corresponding one-sided p-value was ≤ 0.025/2 = 0.0125, or if both one-sided p-values were ≤ 0.025.) · Mean difference (net): 5.6 · 95% CI 3.5 to 7.6Differences in LS means and the two-sided 95% CIs are estimated from pairwise ANOVA (stratified) model.
SecondaryChange From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6

Best corrected visual acuity (BCVA) was tested using the early treatment diabetic retinopathy study (ETDRS) VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 6.

Time frame:
From Baseline to Month 6
Reported as:
Mean · ETDRS letters
Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6
ETDRS lettersGroup IGroup IIGroup III
Baseline53.7 ± 12.6554.2 ± 13.0152.6 ± 12.29
Average Month 1 to Month 664.1 ± 12.7764.9 ± 13.1459.6 ± 12.99
Statistical analysis
  • Group I vs Group II · Cochran-Mantel-Haenszel · p = <0.001 (Non-inferiority could be claimed if the corresponding one-sided p-value was ≤ 0.025.) · Mean difference (net): 0.4 · 95% CI -1.3 to 2.1Differences in LS means and the two-sided 95% CIs are estimated from pairwise ANOVA (stratified) model.
SecondaryThe Average Change in BCVA Score From Baseline to Month 1 Through Month 12

Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 12

Time frame:
From Baseline to Month 12
Reported as:
Mean · ETDRS letters
The Average Change in BCVA Score From Baseline to Month 1 Through Month 12
ETDRS lettersGroup IGroup IIGroup III
Baseline53.7 ± 12.6554.2 ± 13.0152.6 ± 12.29
Average Month 1 to Month 1264.8 ± 12.8265.9 ± 13.2661.2 ± 13.10
SecondaryMean Change From Baseline in Visual Acuity Over Time

Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.

Time frame:
Change from baseline at months 3, 6, and 12
Reported as:
Mean · ETDRS letters
Mean Change From Baseline in Visual Acuity Over Time
ETDRS lettersGroup IGroup IIGroup III
Month 310.5 ± 9.1310.8 ± 10.094.5 ± 9.35
Month 611.6 ± 10.6612.1 ± 11.579.5 ± 10.50
Month 1212.0 ± 11.5013.1 ± 11.4610.3 ± 12.69
SecondaryCategorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye

ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.

Time frame:
From Baseline to Month 12
Reported as:
Number · Participants
Categorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye
ParticipantsGroup IGroup IIGroup III
Gained≥15 letters or reached 84 letters-Month 3585915
Gained≥10 letters or reached 84 letters-Month 39710724
Gained≥15 letters or reached 84 letters-Month 67173NA
Gained≥10 letters or reached 84 letters-Month 6100121NA
Gained≥15 letters or reached 84 letters-Month 128175NA
Gained≥10 letters or reached 84 letters-Month 12110115NA
SecondaryMean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)

Central sub-field thickness (CSFT) is a variable assessed via Optical Coherence Tomography (OCT). OCT was performed prior to any study drug administration to assess presence of intra, subretinal fluid, or increase of CSFT.

Time frame:
Baseline, Month 3, Month 6, and Month 12
Reported as:
Mean · micrometer
Mean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)
micrometerGroup IGroup IIGroup III
Month 3-66.4 ± 98.68-71.2 ± 81.28-29.1 ± 75.57
Month 6-70.7 ± 73.20-75.1 ± 80.90-59.3 ± 81.82
Month 12-79.4 ± 71.39-80.8 ± 85.93-66.0 ± 93.60
SecondaryNumber of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12

CNV leakage is assessed via fluorescein angiography (center involvement) category: definite, questionable, absent, can't grade, and missing.

Time frame:
From Baseline until Month 12
Reported as:
Number · Participants
Number of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12
ParticipantsGroup IGroup IIGroup III
Baseline - Definite16416076
Baseline - Questionable130
Baseline - Absent141913
Baseline - Can't Grade200
Baseline - Missing122
Month 12 - Definite344326
Month 12 - Questionable642
Month 12 - Absent13312956
Month 12 - Can't Grade220
Month 12 - Missing767
SecondaryNEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12

The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.

Time frame:
Change from baseline at month 3, 6 and 12
Reported as:
Mean · Composite score
NEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12
Composite scoreGroup IGroup IIGroup III
Month 34.7 ± 12.286.1 ± 13.491.7 ± 13.55
Month 65.0 ± 13.405.6 ± 15.42-0.1 ± 15.30
Month 124.4 ± 16.034.7 ± 16.921.3 ± 16.85
SecondaryNumber of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups

To assess treatment pattern with ranibizumab

Time frame:
From Baseline to Month 12
Reported as:
Mean · Injections
Number of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups
InjectionsGroup IGroup IIGroup III With 0.5mg RanibizumabGroup III Without 0.5mg Ranibizumab
Month 32.4 ± 0.532.1 ± 0.84NA ± NANA ± NA
Month 124.6 ± 2.443.9 ± 2.503.2 ± 2.253.8 ± 2.36

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Treatment, approximately 4 years.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group I—7/182 (3.8%)102/182 (56%)
Group II—15/185 (8.1%)116/185 (62.7%)
Group III With 0.5mg Ranibizumab—8/75 (10.7%)50/75 (66.7%)
Group III Without 0.5mg Ranibizumab—0/14 (0%)8/14 (57.1%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventGroup IGroup IIGroup III With 0.5mg RanibizumabGroup III Without 0.5mg Ranibizumab
ArrhythmiaCardiac disorders0/1820/1851/750/14
Coronary artery diseaseCardiac disorders0/1821/1851/750/14
Retinal detachment (Fellow eye)Eye disorders0/1821/1851/750/14
Rectal polypGastrointestinal disorders0/1820/1851/750/14
AppendicitisInfections and infestations0/1820/1851/750/14
Endophthalmitis (Study eye)Infections and infestations0/1820/1851/750/14
Physical examination abnormalInvestigations0/1820/1851/750/14
Shock hypoglycaemicMetabolism and nutrition disorders0/1820/1851/750/14
Type 2 diabetes mellitusMetabolism and nutrition disorders0/1820/1851/750/14
RhabdomyolysisMusculoskeletal and connective tissue disorders0/1820/1851/750/14
Most frequent other events
Showing 10 of 156
Most frequent other events
EventGroup IGroup IIGroup III With 0.5mg RanibizumabGroup III Without 0.5mg Ranibizumab
Retinal haemorrhage (Fellow eye)Eye disorders2/1824/1850/752/14
NasopharyngitisInfections and infestations17/18220/1858/751/14
Upper respiratory tract infectionInfections and infestations14/18212/1856/750/14
Conjunctival haemorrhage (Study eye)Eye disorders8/18214/1852/750/14
ThrombocytopeniaBlood and lymphatic system disorders0/1820/1851/751/14
PalpitationsCardiac disorders1/1820/1850/751/14
Choroidal neovascularisation (Fellow eye)Eye disorders2/1823/1851/751/14
Conjunctivitis allergic (Fellow eye)Eye disorders0/1821/1851/751/14
Conjunctivitis allergic (Study eye)Eye disorders1/1822/1851/751/14
Dry eye (Fellow eye)Eye disorders2/1822/1850/751/14

Baseline characteristics

Randomized Set: consisted of all randomized patients. Patients were considered randomized when they had been given a randomization number.

Age, Continuous
Age, Continuous(Years)Group IGroup IIGroup IIITotal
Mean52.0 ± 12.0151.5 ± 12.1349.1 ± 14.8151.2 ± 12.68
Sex: Female, Male
Sex: Female, Male(Participants)Group IGroup IIGroup IIITotal
Female12811667311
Male546824146
08

Study locations

47 sites
  • Novartis Investigative Site
    Beijing, Beijing 100191, China
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Chongqing, Chongqing 400042, China
  • Novartis Investigative Site
    Shantou, Guangdong 515041, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150001, China
  • Novartis Investigative Site
    Wuhan, Hubei 430060, China
  • Novartis Investigative Site
    Wuhan, Hubei 430070, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210006, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Wu XI, Jiangsu 214023, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Qingdao, Shandong 266011, China
  • Novartis Investigative Site
    Xi'an, Shanxi 710032, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300070, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310009, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325027, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100176, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Chongqing, 400038, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Shanghai, 200092, China
  • Novartis Investigative Site
    Shanghai, China
  • Novartis Investigative Site
    Hongkong, Hong Kong
  • Novartis Investigative Site
    Chandigarh, Haryana 160 030, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560 010, India
  • Novartis Investigative Site
    Vanchiyoor, Kerala 695035, India
  • Novartis Investigative Site
    Bhubaneswar, Orissa 751024, India
  • Novartis Investigative Site
    Chennai, Tamil Nadu 600 015, India
  • Novartis Investigative Site
    Chennai, Tamil Nadu 600006, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641 014, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500 034, India
  • Novartis Investigative Site
    Angamaly, 683572, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Pusan, 614 735, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 02841, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Manila, Metro Manila 1000, Philippines
  • Novartis Investigative Site
    Manila, Metro Manila 1008, Philippines
  • Novartis Investigative Site
    Khon Kaen, THA 40002, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Nakornphathom, 73210, Thailand
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Sep 2016, 36 months.

Results were first posted in Jun 2019, 2 years 9 months after primary completion.

Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 35. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2013
First posted
Aug 14, 2013
StartActual
Sep 11, 2013
Primary completionActual
Sep 14, 2016
CompletionActual
Sep 14, 2016
Results first posted
Jun 24, 2019
Last update
Jun 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01922102
Responsible party
Sponsor
First posted
Aug 14, 2013
Start date
Sep 11, 2013
Primary completion
Sep 14, 2016
Completion
Sep 14, 2016
Results posted
Jun 24, 2019
Last update
Jun 24, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion